Mayzent (siponimod) Patient Assistance Program
Don’t let the high cost of brand selective S1P receptor modulator disrupt your secondary progressive multiple sclerosis treatment. We help eligible patients access Mayzent (siponimod tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Mayzent (siponimod) is FDA-approved for treatment of relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Selective sphingosine 1-phosphate (S1P) receptor 1 and 5 modulator — refined S1P selectivity vs Gilenya (fingolimod). Once-daily oral therapy.
- Without assistance, Mayzent costs commonly run approximately $8,000–$10,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Mayzent for a flat $69.95 per month.
- Other S1P receptor modulators for MS: Gilenya (fingolimod — brand and generic; earlier, less selective), Zeposia (ozanimod — brand; S1P1/5 selective), Ponvory (ponesimod — brand; S1P1 selective). Non-S1P oral MS therapy: Tecfidera generic (dimethyl fumarate), Vumerity brand (diroximel fumarate), Aubagio generic (teriflunomide), Mavenclad (cladribine). High-efficacy monoclonal antibody DMTs: Ocrevus IV every 6 mo, Kesimpta SC monthly, Tysabri IV every 4 wk, Lemtrada IV rare-course, Briumvi IV. Injectable DMTs (older) — interferons, glatiramer acetate.
What is Mayzent Prescription Assistance Program?
The Mayzent Patient Assistance Program helps eligible patients access this selective S1P receptor modulator at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Mayzent PAP enrollment for a flat $69.95 per month — so you never face a gap in Mayzent MS therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Mayzent enrollment — so you never face a gap in your multiple sclerosis treatment.
Pharmacy Price Comparison
- Without assistance, Mayzent costs thousands per month at specialty pharmacies. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Tecfidera generic (alt oral) | ~$1,000/mo | Cheap oral MS alt |
| Specialty pharmacy | ~$8,500/mo | Save substantially |
| Walgreens Specialty | ~$9,500/mo | Save substantially |
| CVS Specialty | ~$10,000/mo | Save substantially |
| 340B-eligible institution | ~$7,500/mo | Save substantially |
| Gilenya generic (alt S1P) | ~$1,500/mo | Cheap generic S1P alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Mayzent — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Mayzent Prescription Program?
The Mayzent Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Generic Gilenya (fingolimod) and generic Tecfidera offer significant cost savings for oral MS therapy. Newer selective S1P modulators (Mayzent, Zeposia) may have improved cardiac and macular edema profiles vs older Gilenya.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Mayzent assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Mayzent is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Mayzent:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $8,000–$10,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Mayzent assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Mayzent Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Mayzent:
Mayzent is a selective S1P1/5 receptor modulator — with refined receptor selectivity compared to Gilenya (fingolimod). Once-daily oral MS disease-modifying therapy — it sequesters lymphocytes in lymph nodes, reducing CNS infiltration.
How It Works:
Sphingosine 1-phosphate (S1P) receptor modulators cause lymphocytes to remain sequestered in lymph nodes — reducing pathological lymphocyte infiltration into the central nervous system in MS. Effective disease-modifying mechanism for relapsing MS. First-generation S1P modulator fingolimod (Gilenya) acts at S1P1, S1P3, S1P4, and S1P5 — broader receptor activity contributing to cardiac (bradycardia) and other off-target effects. Siponimod (Mayzent) is selective for S1P1 and S1P5 — refined selectivity may reduce off-target effects. Once-daily oral. Requires CYP2C9 genotype-based dosing (poor metabolizers require a reduced dose or alternative). Also FDA-approved specifically for active secondary progressive MS (Gilenya not approved for SPMS). Related agents: Zeposia (ozanimod — S1P1/5 selective), Ponvory (ponesimod — S1P1 selective).
Form and Use:
Mayzent tablets. Titration up to 2 mg once daily maintenance (or lower for CYP2C9 poor metabolizers). Requires CYP2C9 genotype testing before starting. First-dose observation for cardiac monitoring is not required for Mayzent in most patients (unlike Gilenya). Ophthalmology baseline (macular edema risk). Skin cancer screening.
Generic Availability:
No generic Mayzent. Other S1P receptor modulators for MS: Gilenya (fingolimod — brand and generic; earlier S1P modulator with less receptor selectivity), Zeposia (ozanimod — brand; S1P1/5 selective similar to Mayzent), Ponvory (ponesimod — brand; S1P1 selective). Non-S1P oral MS therapy: Tecfidera generic (dimethyl fumarate), Vumerity brand (diroximel fumarate), Aubagio generic (teriflunomide), Mavenclad (cladribine — pulsed course). High-efficacy monoclonal antibody DMTs: Ocrevus (ocrelizumab IV every 6 mo), Kesimpta (ofatumumab SC monthly), Tysabri (natalizumab IV every 4 wk), Lemtrada (alemtuzumab IV rare-course), Briumvi (ublituximab IV). Injectable DMTs (older): interferons (Betaseron, Rebif, Avonex, Plegridy), glatiramer acetate (Copaxone brand and generic Glatopa). National MS Society and MS Navigator resources.
Warnings:
Bradycardia and cardiac conduction effects (first-dose bradycardia — less clinically significant than Gilenya; check ECG and cardiac history), macular edema (baseline ophthalmology; periodic monitoring), decreased pulmonary function (spirometry monitoring), hepatotoxicity (monitor LFTs), fetal risk (contraindicated in pregnancy — teratogenic; effective contraception during and for weeks after discontinuation), lymphopenia (persistent lymphocyte suppression — monitor CBC), progressive multifocal leukoencephalopathy (rare but reported with S1P modulators), skin cancer (increased basal cell carcinoma — periodic skin monitoring), infections (increased risk — vaccinate before starting if possible, avoid live vaccines during and for 3+ months after). Other: fatigue, headache, elevated LFTs. CYP2C9 genotype required — dose reduction or contraindication for poor metabolizers.
FAQ (Frequently Asked Questions)
How much does Mayzent cost without insurance?
$8,000–$10,000 per month at specialty pharmacies. Generic fingolimod (Gilenya generic — earlier S1P modulator) is $1,000–$1,500/month — significantly cheaper if the S1P modulator class is appropriate. Zeposia and Ponvory are similarly priced to Mayzent (brand).
How is Mayzent different from Gilenya?
Both are S1P receptor modulators for MS. Gilenya (fingolimod) acts at S1P1, S1P3, S1P4, and S1P5 — broader receptor activity contributing to cardiac (bradycardia — first-dose observation historically required) and other off-target effects. Mayzent (siponimod) is selective for S1P1/5 — refined selectivity may reduce off-target effects. Mayzent doesn’t require first-dose cardiac monitoring in most patients and is additionally FDA-approved for active secondary progressive MS (Gilenya is not). Generic Gilenya is significantly cheaper.
Why do I need CYP2C9 genotype testing before Mayzent?
Siponimod is metabolized by CYP2C9. CYP2C9 poor metabolizers (particularly *3/*3 genotype) require dose reduction or alternative therapy — otherwise there is risk of excess drug exposure and adverse effects. Genotype testing is required before initiation — different from Gilenya, which doesn’t require genotype testing.
What is Mayzent's indication for secondary progressive MS?
Mayzent is specifically FDA-approved for active secondary progressive MS (SPMS) — MS that has evolved from relapsing-remitting into progressive worsening but still has ongoing inflammatory activity (relapses or MRI activity). It is distinguished from primary progressive MS (Ocrevus indicated) and non-active SPMS. Mayzent slowed disability progression in SPMS in the EXPAND trial.
What are Mayzent side effects?
Bradycardia (first-dose, generally mild), macular edema (ophthalmology monitoring), decreased pulmonary function, hepatotoxicity (monitor LFTs), lymphopenia (persistent — monitor CBC), infections (increased risk), skin cancer (basal cell carcinoma — periodic screening), rare PML. Fatigue and headache are common. Contraindicated in pregnancy.
Take Control of Your Medication Costs
MS disease-modifying therapy preserves neurological function long-term. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.